Citius Pharmaceuticals Announces FDA Acceptance of IND Applicati
CTXR: Citius Pharmaceuticals, Inc.
2022-02-15 09:15:00
Citius Pharmaceuticals Announces FDA Acceptance of IND Application for its Phase 2b Study of Halo-Lido for the Prescription Treatment of Hemorrhoids
2022-02-15 09:15:00
Citius Pharmaceuticals Announces FDA Acceptance of IND Application for its Phase 2b Study of Halo-Lido for the Prescription Treatment of Hemorrhoids
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.